A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

Inclusion Criteria Patients must have: * HIV positivity. * CD4 count \>= 500 cells/mm3. * No evidence of AIDS, persistent diarrhea, fever, oral hairy leukoplakia, herpes varicella-zoster (multidermatomal), oral candidiasis, opportunistic infections, severe cytomegalovirus infection, or disseminated or chronic herpes simplex. * Successful establishment of EBV transformed B lymphoblastoid cell line. NOTE: * Most patients in group 2 must possess one or more HLA types A33, B8, B27, or Bw62. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Active syphilis. * Positive circulating hepatitis B virus antigen. * Active clinically significant medical problems. * Evidence of psychiatric, medical, or substance abuse problems that would affect ability to participate on study. * Occupational or other responsibilities that would prevent completion of study. Concurrent Medication: Excluded: * Other HIV immunotherapeutic. * Zidovudine or analog. * Investigational therapies for HIV. Patients with the following prior conditions are excluded: * History of cancer unless surgically excised with reasonable assurance of cure. * History of anaphylaxis or other serious adverse reactions to vaccines. * History of serious allergic reaction to any substance that required hospitalization or emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasms, or hypotension). * History of autoimmune disease or use of immunosuppressive medications. * History of suicide attempts or past psychosis. Prior Medication: Excluded within the past 6 months: * HIV immunotherapeutic. * Zidovudine or analog. * Investigational therapies for HIV. Illicit drug use within past 30 days.